cabazitaxel
Pharmaranks rates Cabazitaxel 3.6/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Cabazitaxel is a medication used to treat Prostatic Neoplasms.
Generic · by Actavis
Generic of Jevtana Kit
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Cabazitaxel
- Form
- Solution
- Strength
- Cabazitaxel 60MG/6ML (10MG/ML)
- Type
- Prescription (Rx)
- Brand or generic
- Generic
- May treat
- prostatic neoplasms
- Manufacturer
- Actavis
- FDA application
- NDA207970
- Availability
- Discontinued (per FDA)
May treat (source: NIH RxClass)
Dosage forms
Solution
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Cabazitaxel treat?
- Cabazitaxel (Cabazitaxel) may be used to treat prostatic neoplasms, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Cabazitaxel rated?
- pharmaranks gives Cabazitaxel a composite score of 3.6 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Cabazitaxel?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Cabazitaxel. To pay less, Cabazitaxel is already a generic — usually the lowest-cost version — so the main levers are comparing cash prices between pharmacies and using a pharmacy discount-card service. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Cabazitaxel?
- Cabazitaxel is marketed by Actavis. You can see Actavis's full profile, rating, and other products on pharmaranks.
- Is Cabazitaxel a brand-name or generic drug?
- Cabazitaxel is a generic medication; its active ingredient is Cabazitaxel. Generics contain the same active ingredient as the brand-name original and are usually lower cost.
- Is Cabazitaxel available over the counter?
- No. Cabazitaxel is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Cabazitaxel come in?
- Cabazitaxel is currently marketed as solution, per the FDA's National Drug Code Directory.
- Is Cabazitaxel FDA-registered?
- Cabazitaxel is on record with the U.S. FDA under application number NDA207970. You can verify this on its official FDA label.
- Has Cabazitaxel been recalled by the FDA?
- Cabazitaxel has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Cabazitaxel safe?
- There's no single safe-or-not verdict. pharmaranks gives Cabazitaxel a recall-safety score of 72/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about Cabazitaxel
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 2,052 reports naming Cabazitaxel, and the FDA flagged 96% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- malignant neoplasm progression191 reports
- fatigue149 reports
- anaemia138 reports
- prostatic specific antigen increased138 reports
- febrile neutropenia134 reports
- diarrhoea113 reports
- metastases to bone113 reports
- neutropenia104 reports
Read these as a signal, not a rate. A report does not mean Cabazitaxel caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Cabazitaxel head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
cabazitaxel
72/100